FRESENIUS MEDICAL CARE AG |
Market Closed -
Other stock markets
|
After market 03:59:55 pm | |||
| 38.38 EUR | -0.95% |
|
38.07 | -0.81% |
| Sales 2024 * | 19.57B 21.2B | Sales 2025 * | 20.32B 22.01B | Capitalization | 11.37B 12.32B |
|---|---|---|---|---|---|
| Net income 2024 * | 651M 705M | Net income 2025 * | 964M 1.04B | EV / Sales 2024 * | 1.09 x |
| Net Debt 2024 * | 9.92B 10.74B | Net Debt 2025 * | 8.98B 9.73B | EV / Sales 2025 * | 1 x |
| P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
11.9
x | Employees | 117,128 |
| Yield 2024 * |
2.78% | Yield 2025 * |
3.36% | Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fresenius Medical Care AG
More recommendations
More press releases
More news
| 1 day | +0.44% | ||
| 1 week | -6.69% | ||
| Current month | -1.69% | ||
| 1 month | -2.43% | ||
| 3 months | +9.82% | ||
| 6 months | +7.33% | ||
| Current year | +2.56% |
1 week
38.33
40.90
1 month
36.5742.12
Current year
33.8842.12
1 year
30.1649.62
3 years
25.9571.14
5 years
25.9581.10
10 years
25.9593.82
| Managers | Title | Age | Since |
|---|---|---|---|
Helen Giza
CEO | Chief Executive Officer | 56 | 19-10-31 |
Martin Fischer
DFI | Director of Finance/CFO | 47 | 23-09-30 |
Franklin Maddux
CTO | Chief Tech/Sci/R&D Officer | 65 | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 16-05-11 |
Shervin Korangy
BRD | Director/Board Member | 50 | 23-07-13 |
Marcus Kuhnert
BRD | Director/Board Member | 56 | 23-07-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.48% | 202 M€ | -.--% | ||
| 1.12% | 2 M€ | +13.56% | - | |
| 0.80% | 79 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 38.38 | -0.95% | 515 357 |
| 24-05-22 | 38.75 | -2.15% | 450,619 |
| 24-05-21 | 39.6 | -2.20% | 447,946 |
| 24-05-20 | 40.49 | +0.07% | 236,272 |
| 24-05-17 | 40.46 | -3.02% | 439,279 |
Delayed Quote Xetra, May 23, 2024 at 09:58 am EDT
More quotes
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Calendar
2024-07-29
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
38.75
EUR
Average target price
39.84
EUR
Spread / Average Target
+2.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.56% | 12.32B | |
| +17.46% | 83.4B | |
| -27.75% | 72.11B | |
| 0.00% | 27.04B | |
| -11.99% | 16.96B | |
| +0.11% | 16.86B | |
| +2.78% | 15.76B | |
| +73.07% | 13.33B | |
| +1.81% | 12.76B | |
| +71.42% | 12.74B |
- Stock Market
- Equities
- FME Stock
